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The canine transmissible venereal tumor (TVT) affects the external genitalia of dogs by the natural 
transplant of viable tumor cells. Thus, this research aimed to diagnose and characterize TVT 
morphological patterns, identify the insertion of the LINE-1 element in C-MYC gene, by means of the 
polymerase chain reaction (PCR), and evaluate the immunohistochemical expression of C-MYC, p53, 
p21 and p27 proteins. The relationship between C-MYC and p53 proteins and their interference on the 
expression of p21 and p27 were also studied. For that, 20 samples of naturally occurring TVT were used, 
subjected to cytopathological, histopathological and immunohistochemical analysis, and to molecular 
diagnosis of neoplasia. The increased tissue expression and the correlation among C-MYC, p53, p21 and 
p27 proteins indicate reduction and/or loss of their functionality in the TVT microenvironment, with 
consequent apoptotic suppression, maintenance of cell growth and progression of neoplasia. 
 




O tumor venéreo transmissível canino (TVT) afeta a genitália externa de cães pelo transplante natural de 
células tumorais viáveis. Assim, esta pesquisa teve como objetivo diagnosticar e caracterizar TVT em 
padrões morfológicos, identificar a inserção do elemento LINE-1 em gene C-MYC, por meio da reação 
em cadeia da polimerase (PCR), e avaliar a expressão imuno-histoquímica do C-MYC, p53, p21 e p27. A 
relação entre C-MYC e as proteínas p53 e a sua interferência na expressão de p21 e p27 foram também 
estudadas. Para isso, foram utilizadas 20 amostras de ocorrência natural de TVT, submetido a exame 
citopatológico, histopatológica e imuno-histoquímica e ao diagnóstico molecular de neoplasia. A 
expressão aumentada do tecido e a correlação entre a C-MYC e as proteínas p53, p21 e p27 indicam 
redução e/ou perda de funcionalidade na TVT em seu microambiente, com consequente supressão 
apoptótica, manutenção do crescimento celular e progressão da neoplasia. 
 




The canine transmissible venereal tumor (TVT) 
has unique features. Since it is not originated 
from the neoplastic transformation of normal 
cells, its growth and evolution occur as a result 
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of transmitting a clone of tumor cells from 
affected dogs to healthy ones. It is characterized 
as a round cell neoplasia, with single core and 
vacuolated cytoplasm (Amaral et al., 2012). 
Nevertheless, there are differences among cells 
that enable the classification of TVT according 
to a morphological, lymphocytoid, plasmacytoid 
or mixed pattern (Floréz et al., 2012). 
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The insertion of the LINE-1 element in the C-
MYC gene refers to a specific molecular 
rearrangement of TVT. Thus, its identification is 
described as a complementary diagnostic method 
of neoplasia, and the polymerase chain reaction 
(PCR) consists of a highly specific molecular 
tool to verify that change (Fonseca et al., 2012). 
 
The C-MYC gene is an aproto-oncogene 
regulator of the cell cycle with activity in 
different molecular pathways (Faria and 
Rabenhorts, 2006). Thus, in one of its regulatory 
pathways, C-MYC inhibits the function of p27 
kinase inhibitor protein. It is speculated that this 
gene also interferes on the inhibition of tumor 
suppressor genes such as p21, p57, p15 and  
p16. C-MYC also acts triggering apoptotic 
mechanisms by the indirect activation of the p53 
tumor suppressor gene, through p19 (Pelengaris 
et al., 2003). 
 
P53 protein has an antagonistic function to C-
MYC proteins, because it acts on check points 
activating tumor suppressor genes such as p21, 
which blocks the progression of the cycle 
(Sánchez-Servín et al., 2009). Although the p53 
expression is described in TVT cells, there are no 
reports about this relationship, as well as C-MYC 
proteins, with those inhibiting the cell cycle and 
dependent on kinases (Moro et al., 2010). 
 
This study aimed to diagnose and characterize 
TVT morphological patterns by cytopathological 
and histopathological examinations, identify the 
insertion of the LINE-1 element in the C-MYC 
gene through the polymerase chain reaction 
(PCR), the immunohistochemical expression of 
C-MYC on coprotein and p53, p21 and p27 
tumor suppressor proteins and the interference of 
C-MYC and p53 proteins in the p21 and p27. 
 
MATERIALS AND METHODS 
 
The research was approved by the Comitê de 
Ética em Pesquisa of the Universidade Federal 
de Goiás under protocol number 123/11. Twenty 
dogs affected by naturally occurring TVT were 
used, with no restriction of age, gender and 
breed, not undergoing prior chemotherapy and 
with a tumor located primarily on external 
genitalia. In order to obtain clinical data, the 
animals were subjected to complete physical 
examination and the information was recorded in 
individual clinical evaluation protocols. 
A biopsy fragment was obtained from  
every tumor, which, after resection, was 
sectioned into three fragments used  
for the preparation of the cytopathological 
sample (AT1), histopathological and 
immunohistochemical analyses (AT2), and 
molecular diagnosis of TVT (AT3). In order to 
compose the negative control group of the 
molecular diagnosis of TVT, a sample from a 
second neoplastictype (mastocytoma) and two 
samples of peripheral blood from healthy 
animals were obtained. Three milliliters of whole 
blood were collected from those samples, being 
packed in vacutainer tubes with EDTA (Becton, 
Dickinson & Company, USA), and frozen at -
20°C for DNA extraction and molecular analysis. 
 
For cytopathological analysis, the samples 
obtained by the imprinting of the AT1 fragment 
were fixed in methanol for 5min and subjected  
to Giemsa staining for 30min. The 
cytomorphological diagnosis of TVT was 
established according to Cowell et al. (2008). 
Four-micrometer histological sections were made 
from the AT2 fragment included in paraffin, and 
then, they were distended on histological slides 
and stained by Hematoxylin and Eosin (HE). The 
histomorphological evaluation of TVT followed 
the criteria by Santos et al. (2008). 
 
The samples evaluated in the cytopathological 
and histopathological analyses were also used  
for the classification of the predominant 
morphological pattern of TVT and followed the 
criteria proposed by Floréz et al. (2012). The 
apoptotic index of TVT was evaluated in 
histological slides stained by HE, according to 
methodology adapted from Gonzalez et al. 
(2000). The parameter was estimated according 
to the discrete, moderate or sharp scores. 
 
The immunohistochemical analyses were 
subjected to the tissue microarray (TMA) 
technique, according to the descriptions by 
Kononen et al. (1998) and Bubendorf et al. 
(2001). Mouse anti-human C-MYC Ab-2 
monoclonal antibody, clone 9E10.3 (Thermo 
Fisher ScientificNeomarkers, MS-139-P0) were 
used, diluted at 1:50; mouse anti-human p53 
monoclonal antibody, clone DO-7 (Dako 
M7001), diluted at 1:500; mouse anti-human 
p21WAF1/Cip1 monoclonal antibody, clone SX118 
(Dako M7202), diluted at 1:50; and mouse anti-
human and p27Kip1 monoclonal antibody, clone 
SX53G8 (Dako M7203), diluted at 1:200. Then, 
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protein blocking was conducted (Post Primary 
Block, Novo Link Max Polymer RE7260-K, 
United Kingdom) and the incubation was done in 
signal amplification system (Novo link Polymer, 
Novo Link Max Polymer RE7260-K, United 
Kingdom). 
 
For the visualization of the reaction, the sections 
were submerged in diaminobenzidine (DAB) 
solution (100mg of 3.3`diaminobenzidine 
tetrahydrochloride, (Sigma, D-5637, USA), 1mL 
of dimethylsulfoxide (DMSO), 1mL of H2O2 20 volumes at 6% and 100mL of PBS buffer), away 
from the light. Following, the sections were 
washed, stained with Harris hematoxylin, 
diaphanized and mounted with coverslipand 
synthetic resin (Entellan, Merck, 1.07961, 
Germany). As positive control of the reactions, 
samples of human breast carcinoma (C-MYC), 
canine squamous cell carcinoma (p-53) and 
human colon carcinoma (p-21 and p-27) were 
used. For the negative control of the reactions, a 
10mMpH7.4 PBS buffer solution was used to 
substitute the primary antibodies. 
 
In an optical microscope, TMA slides were 
evaluated regarding immunolabeling, following 
the analysis of the intensity (I) of labeling 
according to (I0) absent, (I1) discrete, (I2) 
moderate and (I3) sharp scores (Fig. 1). The 
percentage (C) of immunolabeled cells in every 
TVT morphological pattern was also measured, 
in order to evaluate the correlation between C-
MYC and p53, C-MYC and p21/p27, and p53 
and p21/p27 proteins. For that, the scores (C0) 
absence of immunolabeled cells, (C1) 
immunolabeling of 1-25%, (C2) of 26-50%, (C3) 
of 51-75% and (C4) of 76-100% of the cells 
were considered. 
Figure 1. Staining intensity scores assigned to the labeling analysis in C-MYC, p53, p21WAF1/Cip1 and 
p27Kip1 antibodies in canine TVT. 
 
The extraction of genomic DNA from positive 
samples and negative control of TVT, as well as 
the analyses for the molecular identification were 
conducted according to the descriptions by 
Fonseca et al. (2012). The samples were 
evaluated regarding the presence of the 
molecular rearrangement of the LINE-1 element 
in the C-MYC gene, by the PCR technique. For 
that, the primers MYC.S, LINE.A, HBGA.S and 
HGBA.A were used. The reaction obtained from 
the HBGA.S and HGBA.A primers, which 
amplifies a 480pb segment of the human 
hemoglobin gene, composed the internal positive 
control of the PCR. 
 
The reaction was composed of different elements 
and concentrations, being 0.2µm of every primer, 
0.2mMof dNTPs solution, polymerase TaqDNA 
buffer for a final concentration of 1X, 2U of 
polymerase TaqDNA, magnesium chloride in 
optimum concentration for every pair of primer 
and approximately 10ng of genomic DNA and 
H2O2 enough to make up a final volume of 25µL. The amplification reaction was performed in a 
Swift MaxPro SWT thermal cycler (ESCO 
MICRO Pte LTD.), programmed to perform a 
sequential protocol consisting of a denaturation 
cycle at 94oC/min. After the end of the  
PCR procedure, the gel was stained with 
0.3µg/mL of ethidium bromide and analyzed by 
electrophoresis in 1% agarose gel. 
 
The data relating to the diagnosis, the 
morphological classification, the identification of 
the LINE-1 element in the C-MYC gene, the 
expression and the intensity of C-MYC, p53, p21 
and p27 immunolabeling were analyzed 
descriptively. For the correlation analysis of the 
immunolabeling percentage between C-MYCand 
p53 proteins, as well as among C-MYC, p21, and 
p27 and among p53, p21, and p27, the 
nonparametric test of Spearmann was applied 
with the significance level of 5% (P≤0.05). 
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RESULTS 
 
The cytopathological analysis enabled better 
characterization of the cell type, with lower 
image distortion when compared to 
histopathological analysis. Therefore, the 
predominant morphological pattern of TVT 
(Figure 2) was established by cytopathological 
analysis, observing predominance of the 
plasmacytoid type, with nine cases (45%) of the 
total of the samples analyzed. The second most 
common type was the lymphocytoid, observed in 
six cases (30%), followed by the mixed type in 
five cases (25%) of the total of tissues examined. 
The apoptotic TVT index was discrete in 100% 
of the samples analyzed. 
 
 Figure 2. Photomicrographs of morphological patterns of canine TVT cells by cytopathological 
examination. (A) The Lymphocytoid pattern. Round cells, with large nuclei and scant cytoplasm, similar 
to lymphocytes (black arrow). (B) Plasmacytoid pattern. Cells with more abundant cytoplasm and 
eccentric nuclei, with lower nucleus/cytoplasm ratio (red arrow). (C) Mixed pattern. Lymphocytoid (black 
arrow) and plasmacytoid (red arrow) morphology cells. Giemsa, 400x. 
 
In Figure 3, the molecular rearrangement of the 
LINE-1 element in the C-MYC gene is 
identified, used for the complementary diagnosis 
of TVT. The genomic DNA of the canine 
transmissible neoplasia, columns 1 to 19, 
amplified a fragment of approximately 340pb 
that characterizes the LINE-1/C-MYC molecular 
rearrangement, and a second fragment with an 
approximate molecular weight of 480pb, from 
the human hemoglobin gene, which represents 
the internal positive control of the reaction. 
Columns 20, 21, 22 and 23 represent the negative 
control group. The amplification of a segment of 
the genomic DNA of mastocytoma, the second 
neoplastic type considered in the study, is shown 
in column 20. Only the fragment of 
approximately 480pb was amplified, with total 
absence of amplification regarding the 340pb 
band (light blue arrow). Columns 21 and 22 refer 
to the analysis of the amplification of DNA from 
whole blood samples of healthy dogs. Column 21 
represents the absence of amplification of the 
LINE1/C-MYC rearrangement (yellow arrow). 
Column 22 shows the reaction between the blood 
samples and the human hemoglobin gene (red 
arrow). Column 23 (green arrow) represents the 
internal negative control of the PCR, with total 
absence of amplification, due to the absence of 
DNA. 
 
The immunohistochemical analysis showed 
labeling for C-MYC, p53, p21, and p27 proteins 
in 100% of the samples, regardless of the 
morphological pattern of TVT (Figure 4). 
However, variation in immunolabeling was 
observed when the intensity scores for the 
lymphocytoid, plasmacytoid, and mixed types 
were applied. For C-MYC protein, the scores 
were I2 and I3 in the lymphocytoid type, with no 
predominance of either of them. In the case of 
plasmacytoid and mixed patterns, there was 
predominance of the I3 score. For p53, the I1, I2 
and I3 scores were observed on the 
lymphocytoid type, also with no predominance 
of any score. In the case of plasmacytoid, the 
predominant score was the I2, followed by I3 
and I1, respectively, and, in the mixed, the 
labeling score was I3 in all samples. The 
intensity of p21 in the lymphocytoid and 
plasmacytoidtypes was predominantly I3 score, 
followed by I2 and I1, while, in the mixed type, 
the score was I3. As for the p27, the intensity 
was I2 and I3 in the lymphocytoid type and I3 in 
the plasmacytoid and mixed types. 
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 Figure 3. Molecular diagnosis of canine transmissible venereal tumor (TVT) by the polymerize chain 
reaction (PCR). Column M - molecular weight marker Ruler 1kb Plus Gene. Columns 1 to 19 - product of 
the amplification from the genomic DNA of TVT. Column 20 demonstrates the amplification of the 
genomic DNA of the mastocytoma, represented by the light blue arrow. Columns 21 and 22 represent the 
amplification of the DNA in whole blood samples of healthy dogs, marked with the yellow and red 
arrows, respectively. Column 23 (green arrow) represents the internal negative control of the PCR 
(absence of DNA). 
 
 Figure 4. Photomicrographs of immunohistochemical reactions in canine TVT. (A) C-MYC. Cytoplasmic 
labeling in I3 and C4 scores for labeling intensity and percentage of labeled cells. (B) p53. Nuclear 
labeling in the I3 and C4 scores for labeling intensity and percentage of labeled cells. (C) p21. Nuclear 
labeling in the I2 and C4 scores for labeling intensity and percentage of labeled cells. (D) p27. Nuclear 
labeling in theI2 and C1 scores for labeling intensity and percentage of labeled cells. IHC, 250x. 
 
Insertion of the LINE-1... 
Arq. Bras. Med. Vet. Zootec., v.68, n.3, p.658-666, 2016 663 
As for the immunolabeling percentage of every 
protein in the morphological patterns of TVT, 
there was maximum expression (C4) of C-MYC 
and p53 in the lymphocytoid, plasmacytoid and 
mixedtypes. For p21, there was predominance of 
the C2 score, followed by C3 and C4, both for 
the lymphocytoid and the plasmacytoid types. 
On the mixed type, there was a predominance of 
C2, followed by C3. Regarding the p27, there 
were C2 scores, followed by C3 and C1 in the 
lymphocytoid type. In the plasmacytoid, there 
was predominance of C1, followed by C2 and 
C3, while in the score there was the C3 score, 
followed by C2. 
 
In the correlation analysis, there was correlation 
in the percentage of immunolabeled cells 
between C-MYC and p53 proteins (P>0.05) for 
all morphological patterns of TVT. The results of 
the analyses of correlation among C-MYC, p21, 
and p27 and among p53, p21, and p27 proteins 
demonstrate correlation (P>0.05) for most of the 
proteins considered, except in the analysis 





In this research, the plasmacytoid type occurred 
most frequently, followed by the lymphocytoid 
and mixed types, respectively. Similar results 
were described by Amaral et al. (2007) and 
Gaspar et al. (2010), who found greater 
occurrence of the plasmacytoid pattern in the 
genital samples and also in the primary or 
metastatic extra genital samples. 
 
PCR results prove the high sensitivity of the test 
for the detection of rearrangement of the LINE-1 
element in the C-MYC gene in TVT, since all the 
samples of the transmissible neoplasia studied 
amplified a fragment of approximately 340pb, 
which characterizes such rearrangement, 
corroborating the observations by O’Neill 
(2011). It should be highlighted that there was no 
amplification in the other samples considered in 
this study. Although Spin et al. (2010) have 
confirmed that this change is characteristic of 
TVT when compared to the analysis of this same 
rearrangement in the blood of healthy animals, 
they did not mention if such occurrence is 
specific for this neoplastic type. However, the 
absence of the LINE-1/C-MYC molecular 
rearrangement in a canine mastocytoma sample 
of this study suggests that such molecular change 
is specific to TVT. 
 
The MYC.S and LINE.A primers prepared for 
this research were specific for the identification 
of the amplification of a DNA fragment 
including approximately 340pb, being in 
accordance with the methodology by Spin et al. 
(2010) and Fonseca et al. (2012). However, it 
differed from the results presented by other 
authors like Park et al. (2006), who identified a 
550pb amplification responsible for the 
formation of the LINE-1/C-MYC rearrangement 
in TVT. Since the LINE-1 element has a 
sequence of 1,378pb inserted into the C-MYC 
gene, the differences in amplifications are 
justified by virtue of the use of primers that 
configure different gene regions in this 
rearrangement (Murchison, 2009). 
 
Although Andrade et al. (2007) have mentioned 
the concern about the reduced area of the 
samples in the representativeness of important 
and decisive findings concerning the technique to 
process the samples for immunohistochemical 
analysis, the TMA, in this study, such method 
enabled the analysis of the different labels, with 
lower cost, and greater agility, not affecting the 
accuracy of the results. 
 
Considering the criterion of immunolabeling 
intensity, in which the fraction of the labeled cell 
area is evaluated (Matos et al., 2006), it is 
possible to state that C-MYC, p53, p21, and p27 
proteins are present in all TVT samples. In this 
context, despite the variation of immunolabeling 
intensity among proteins, it was subtle among the 
different morphological patterns of TVT. 
 
On the other hand, the immunolabeling 
quantification, given by the analysis of the cell 
labeled percentage compared to the total of cells 
in the sample, enables the finding of the level of 
tissue accumulation in those proteins and 
evaluates the interactions among them. It also 
enables the indirect recognition of the possible 
mechanisms involved in the growth and 
progression of neoplasia. Matos et al. (2006) and 
Trompieri-Silveira et al. (2009) also adopted the 
immunolabeling percentage parameter to 
quantify immunolabeled cells for different 
proteins. In that sense, Trompieri-Silva et al. 
(2009), considering the percentage of labeled 
cells, compared the variation of the 
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immunolabeling of the anti-CD3 antibody among 
the progression and regression phases of TVT, 
and there were differences in the amount of T 
lymphocytes in those phases. 
 
The over expression of the C-MYC protein in all 
morphological types of TVT, represented by the 
C4 score of the percentage of labeled cells, can 
be attributed to the occurrence of mutation of the 
C-MYC gene, initially, by the occurrence of the 
molecular rearrangement proven by the PCR 
technique. According to Faria and Rabenhorts 
(2006), differentiated cells express low levels of 
C-MYC, due to their short half-life. Thus, it is 
suggested that the change in the C-MYC gene 
implies the synthesis of changed protein, with 
reduction or absence of its function and 
accumulation in the neoplastic tissue. This 
protein mutation would assist the maintenance of 
cell growth and the tumor progression, once the 
C-MYC, when functional, acts on the tissue 
integrity inducing the cell apoptosis from 
different pro-apoptotic pathways, including the 
indirect activation of BAX and p53 proteins, as 
well as the connection with the CD95/FAS 
receptor. At the same time, under normal 
conditions, the C-MYC acts on cell proliferation, 
inhibiting the transcription of p21 and p27, 
however, its stimulus ceases when the process is 
completed, in order to avoid the continuous 
stimulus and the resulting disordered cell 
proliferation (Faria and Rabenhorst, 2006, pp. 
165-171). 
 
P53 protein showed a behavior similar to that of 
C-MYC, with over expression (C4) in all 
morphological patterns of TVT. Sánchez-Servín 
et al. (2009) showed polymorphisms in different 
places of P53 gene in TVT samples. In that 
context, although the molecular analysis of P53 
was not applied in this research, it is believed 
that possible gene mutations are the cause of the 
changes in the conformation of the protein, 
leading to increased half-life, occasional function 
loss and accumulation in cells, as described by 
Calazans et al. (2010) and Lima et al. (2012a). In 
the same way, Santos et al. (2008) and Moro et 
al. (2010), while investigating the functional 
impairment of the p53 protein by 
immunohistochemistry, suggested that the 
immunolabeling pattern found indicates 
functional abnormality in p53 and in the protein 
formed from the transcription of the abnormal 
gene, although they have not been able to 
correlate the percentage of labeled cells to the 
prognosis of TVT. 
 
The correlation analysis between C-MYC and 
p53 proteins were conducted in order to 
investigate the interaction between them, 
potentially changed, and the ability of 
inactivation or expression, respectively, of p21 
and p27 tumor suppressor proteins, in different 
TVT cell types. 
 
The relationship between C-MYC and p53, as 
described by Stockmann et al. (2011), is 
associated with the induction of cell apoptosis-
related pathways. Although the statistical 
analysis has confirmed the correlation, in this 
study, there were no morphological changes that 
could characterize the apoptosis. This fact 
supports the hypothesis of dysfunction of C-
MYC and p53 proteins, with consequent 
maintenance of cell growth and progression of 
TVT. Despite the description of apoptosis on 
TVT (Moro et al., 2010), no information was 
found about the impairment of the apoptotic 
mechanism related to the dysfunction of the C-
MYC protein. On the other hand, Santos et al. 
(2008) studied the apoptosis in TVT by 
evaluating the integrity of p53 in experimentally 
transplanted tumors and found that, during tumor 
regression, the p53 expression was higher if 
compared to the progression phase. The authors 
also explain that the higher expression was 
related to the apoptosis of neoplastic cells. On 
the other hand, considering the findings of this 
study, it is possible that the protein functions 
have distinct behaviors in tumors experimentally 
transplanted and in those naturally acquired. This 
suggests that the naturally occurring ones have 
higher aggressive potential, because, in those 
cases, the immune system is blocked by the 
immunophase phenomenon and the tumor cells 
remain in the progression phase longer, and they 
may even evolve to metastasis (Dunnet al., 
2004). 
 
The functionality of C-MYC was also measured 
based on the evaluation of its correlation with 
p21 and p27 proteins. The importance of that 
correlation is justified because of the impact of 
C-MYC for the control of the continued 
progression of the cell cycle, as mentioned by 
Lutz et al. (2002), by the functional inactivation 
of p21 and p27 proteins, which act blocking the 
progression of the cell cycle by inhibiting the 
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cyclin-dependent kinases. The correlation among 
C-MYC, p21, and p27 proteins, observed in this 
study, enables the suggestion that the changes in 
the gene/C-MYC protein set may impair the 
inhibition mechanism of p21 and p27 tumor 
suppressor proteins, maintaining the growth of 
tumor cells and the progression of neoplasia 
continuously and disorderly. However, no 
information was found disagreeing or supporting 
this hypothesis. 
 
Moreover, the correlation among p53, p21, and 
p27 proteins may have contributed to the 
immunolabeling profile of those last two proteins 
in the neoplastic tissue. However, despite the 
presence of those tumor suppressor proteins, 
there was no blocking to the growth of neoplastic 
cells. In that sense, it is speculated that the cell 
growth can also be related to an intrinsic 
mechanism developed by neoplastic cells, 
mediated by C-MYC, for the disorderly 
proliferation, those cells being responsive to new 
stimuli, whether for the growth or blocking of 
the cell cycle, as reported by Alboran et al. 
(2011). Furthermore, considering the tissue 
accumulation, the functionality of p21 and p27 
proteins may also be impaired in TVT samples. 
 
On the other hand, the absence of demonstrated 
correlation between p53 and p21 proteins in the 
TVT plasmacytoid type allows the inference of 
greater tendency to the progression of neoplastic 
cells, due to the absence of blocking in the cell 
cycle induced by this molecular pathway. Studies 
by Gaspar et al. (2010) and Amaral et al. (2012) 
refer to the higher aggressiveness of the 
plasmacytoid type of TVT in studies verifying 
the therapeutic response, the resistance to p-
glycoprotein and the higher concentration of 
injuries to the DNA molecule, respectively. 
Thus, it is suggested that, in the plasmacytoid 
morphological pattern, molecular and protein 
changes are more expressive, culminating in the 
disruption of the p21 induction pathway 




The morphological TVT differences enable the 
classification of neoplasia concerning the 
predominant cell type in lymphocytoid, 
plasmacytoid or mixed types. The insertion of 
the LINE1 element in the C-MYC gene 
characterizes the specific molecular change in 
canine TVT, and the evaluation of this molecular 
rearrangement is useful for the complementary 
diagnosis in cases of undifferentiated TVT. The 
augmented tissue expression and the correlation 
among C-MYC, p53, p21, and p27 proteins 
indicate reduction and/or loss of their 
functionality in the TVT microenvironment, with 
consequent apoptotic suppression, maintenance 
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